Compare PXED & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | PCRX |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | PXED | PCRX |
|---|---|---|
| Price | $30.00 | $23.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $44.29 | $35.33 |
| AVG Volume (30 Days) | 80.6K | ★ 775.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | $6.21 |
| Revenue Next Year | $4.75 | $8.26 |
| P/E Ratio | ★ $10.62 | $48.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $18.80 |
| 52 Week High | $47.08 | $27.64 |
| Indicator | PXED | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 58.70 |
| Support Level | $26.69 | $20.88 |
| Resistance Level | $29.25 | $21.60 |
| Average True Range (ATR) | 1.67 | 0.80 |
| MACD | 0.08 | 0.39 |
| Stochastic Oscillator | 67.71 | 93.52 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.